ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,032.38
0.56%
Dow Jones
44,910.65
0.42%
US Dollar vs MXN
20.3755
0.00%
Brent Oil
71.98
-0.08%
Bitcoin
96,485.37
-1.03%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Reino Unido
  5. LSE
  6. Roquefort Therapeutics Plc (ROQ)

  7. Roquefort Therapeutics Plc (ROQ) Noticias

ROQ

Roquefort Therapeutics (ROQ)

Roquefort Therapeutics Plc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:LSE:ROQ
FechaHoraFuenteTítuloSímboloCompañía
07/11/202401:00RNS Regulatory NewsRoquefort Therapeutics PLC Conversion of Convertible Loan NotesLSE:ROQRoquefort Therapeutics Plc
06/11/202401:00RNS Non-RegulatoryRoquefort Therapeutics PLC STAT-6 siRNA PresentationLSE:ROQRoquefort Therapeutics Plc
27/09/202407:56Alliance NewsAlliance NewsEARNINGS: Kendrick Resources loss narrows; Emmerson CFO to departLSE:ROQRoquefort Therapeutics Plc
27/09/202401:00RNS Regulatory NewsRoquefort Therapeutics PLC Interim Results to 30 June 2024LSE:ROQRoquefort Therapeutics Plc
23/09/202411:51Alliance NewsAlliance NewsRoquefort Therapeutics says MK cell therapy patent approved in JapanLSE:ROQRoquefort Therapeutics Plc
23/09/202401:00RNS Regulatory NewsRoquefort Therapeutics PLC Grant of Japan MK Cell PatentLSE:ROQRoquefort Therapeutics Plc
19/09/202401:00RNS Regulatory NewsRoquefort Therapeutics PLC STAT-6 siRNA Demonstrates Efficacy in ImmunologyLSE:ROQRoquefort Therapeutics Plc
02/09/202401:00RNS Regulatory NewsRoquefort Therapeutics PLC Grant of MK Cell Patent & Licencing UpdateLSE:ROQRoquefort Therapeutics Plc
27/06/202406:46RNS Regulatory NewsRoquefort Therapeutics PLC Results of AGMLSE:ROQRoquefort Therapeutics Plc
20/06/202401:00RNS Regulatory NewsRoquefort Therapeutics PLC Appointment of BrokerLSE:ROQRoquefort Therapeutics Plc
04/06/202401:00RNS Regulatory NewsRoquefort Therapeutics PLC Notice of Annual General MeetingLSE:ROQRoquefort Therapeutics Plc
23/05/202415:25Alliance NewsAlliance NewsTRADING UPDATES: Windward wins deal; Kodal progresses at BougouniLSE:ROQRoquefort Therapeutics Plc
23/05/202401:05RNS Regulatory NewsRoquefort Therapeutics PLC Issue of Convertible Loan Notes & Board ChangesLSE:ROQRoquefort Therapeutics Plc
23/05/202401:00RNS Regulatory NewsRoquefort Therapeutics PLC Midkine Antibody Licencing DealLSE:ROQRoquefort Therapeutics Plc
26/04/202414:59Alliance NewsAlliance NewsEARNINGS AND TRADING: Aura confident in Tiris; Cindrigo enters GermanyLSE:ROQRoquefort Therapeutics Plc
26/04/202401:00RNS Regulatory NewsRoquefort Therapeutics PLC Annual Report & Financial Statements - 31 Dec 2023LSE:ROQRoquefort Therapeutics Plc
05/04/202406:32Alliance NewsAlliance NewsIN BRIEF: Roquefort cancels fundraise after "unusual" stock movementsLSE:ROQRoquefort Therapeutics Plc
05/04/202401:00RNS Regulatory NewsRoquefort Therapeutics PLC Response to Share Price MovementLSE:ROQRoquefort Therapeutics Plc
11/03/202406:12Alliance NewsAlliance NewsRoquefort celebrates "significant milestones" in cancer researchLSE:ROQRoquefort Therapeutics Plc
11/03/202402:00RNS Regulatory NewsRoquefort Therapeutics PLC Positive Results: Midkine mRNA and STAT-6 siRNALSE:ROQRoquefort Therapeutics Plc
06/02/202410:50Alliance NewsAlliance NewsIN BRIEF: Roquefort hails further MK studies, licence talks continueLSE:ROQRoquefort Therapeutics Plc
06/02/202401:00RNS Regulatory NewsRoquefort Therapeutics PLC Operations UpdateLSE:ROQRoquefort Therapeutics Plc
24/11/202301:00UK RegulatoryRoquefort Therapeutics PLC Change of AuditorLSE:ROQRoquefort Therapeutics Plc
06/11/202306:01Alliance NewsAlliance NewsRoquefort Therapeutics MK cell programme shows positive resultsLSE:ROQRoquefort Therapeutics Plc
06/11/202301:00UK RegulatoryRoquefort Therapeutics PLC Significant Mesodermal Killer Cell MilestoneLSE:ROQRoquefort Therapeutics Plc
27/09/202309:43Alliance NewsAlliance NewsEARNINGS: Biome loss widens; Amicorp focused on growth post-IPOLSE:ROQRoquefort Therapeutics Plc
27/09/202301:00UK RegulatoryRoquefort Therapeutics PLC Interim Results to 30 June 2023LSE:ROQRoquefort Therapeutics Plc
22/09/202305:42RNS Non-RegulatoryRoquefort Therapeutics PLC Investor Presentation via Investor Meet CompanyLSE:ROQRoquefort Therapeutics Plc
14/08/202305:07Alliance NewsAlliance NewsRoquefort files patent application for mRNA and RNA therapiesLSE:ROQRoquefort Therapeutics Plc
14/08/202301:00UK RegulatoryRoquefort Therapeutics PLC Expansion of Patent PortfolioLSE:ROQRoquefort Therapeutics Plc
 Showing the most relevant articles for your search:LSE:ROQ

Su Consulta Reciente

CCOM
US30
US 30
NASDAQ
GOOGL
Alphabet
COIN
AVAXUSD
Avalanche
NYSE
DIS
Walt Disney
NYSE
NKE
Nike
FX
EURMXN
Euro vs MXN
USOTC
BNPQY
BNP Paribas (QX)
NYSE
CVX
Chevron
AMEX
XLV
Health Care Select Sector
NASDAQ
TSLA
Tesla
FX
EURUSD
Euro vs US Dollar
NYSE
AXP
American Express
NASDAQ
AAPL
Apple
AMEX
SPY
SPDR S&P 500
NYSE
KO
Coca Cola
FX
USDMXN
US Dollar vs MXN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados

BLACK FRIDAY

ADVFN

Celebrando 25 años Est 1999-2024

Ahorra hasta 60%* en Forex

1 año 40%, 2 años 40% y *3 años 60%

*Durante 3 años $1.035.00 solo $414.00